 This phase 1 first-in-human study evaluates safety and tolerability of SBP-101 in subjects with previously treated pancreatic ductal adenocarcinoma and will identify the maximum tolerated dose MTD. In addition, this study will also assess the pharmacokinetic PK profile and preliminary efficacy of SBP-101. 